Legacy Wealth Asset Management LLC lowered its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,837 shares of the company's stock after selling 20,779 shares during the quarter. Legacy Wealth Asset Management LLC's holdings in Takeda Pharmaceutical were worth $1,865,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in the company. Millennium Management LLC grew its holdings in Takeda Pharmaceutical by 87.1% during the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company's stock worth $56,239,000 after acquiring an additional 2,023,707 shares during the period. FMR LLC grew its stake in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company's stock worth $41,365,000 after purchasing an additional 286,052 shares during the period. Van ECK Associates Corp increased its holdings in Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company's stock valued at $30,149,000 after purchasing an additional 134,407 shares during the last quarter. Managed Asset Portfolios LLC lifted its stake in Takeda Pharmaceutical by 0.3% in the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company's stock valued at $23,001,000 after buying an additional 4,069 shares during the period. Finally, Stifel Financial Corp boosted its holdings in Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company's stock worth $6,266,000 after buying an additional 224,594 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Trading Down 0.8 %
Shares of Takeda Pharmaceutical stock traded down $0.11 during trading on Friday, hitting $12.95. 1,403,137 shares of the company were exchanged, compared to its average volume of 2,034,858. The firm has a market capitalization of $41.19 billion, a P/E ratio of 22.32, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. The firm's fifty day moving average price is $13.39 and its 200 day moving average price is $13.89. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
